A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety of subcutaneous (SC) epoetin beta (NeoRecormon) in adults with solid tumors being treated with platinum-based chemotherapy capable of inducing anemia. The anticipated time on study treatment is 16 weeks, and the target sample size is approximately 208 individuals.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Adults at least 18 years of age

• Presence of solid tumor(s)

• Receiving platinum-based therapy capable of inducing anemia

Exclusion Criteria:

• Red blood cell transfusion within 7 days prior to study drug

• Relevant acute or chronic bleeding requiring therapy within 3 months prior to study drug

• Women who are pregnant or breastfeeding